The latest announcement is out from Cue Biopharma (CUE).
Michael J. Fox was appointed to the board of Cue Biopharma, Inc. and will be compensated under the company’s policy, including stock options vesting over three years. His appointment followed proper corporate governance with no conflicting arrangements. Additionally, Cue Biopharma’s Annual Meeting saw the election of board members, the ratification of their accounting firm, and approval of executive compensation, demonstrating active shareholder engagement and oversight.
For a thorough assessment of CUE stock, go to TipRanks’ Stock Analysis page.
